

Printed from NOAH Compendium (<https://hub21.community.librios.com>). (c) Copyright NOAH Compendium 2026. All Rights Reserved.

Date: Tuesday, February 17, 2026 10:06

[Virbac Limited](#)

Telephone: 01359 243243

Website: www.virbac.co.uk

Carprox Vet 20mg, 50mg and 100mg Tablets for Dogs

Species: Dogs

Therapeutic indication: Pharmaceuticals: Anti-inflammatory preparations: Oral: Other NSAIDs

Active ingredient: Carprofen

Product: Carprox Vet Tablets for Dogs

Product index: Carprox Vet

Incorporating:

Qualitative and quantitative composition

Each tablet contains as active ingredient either 20mg, 50mg or 100mg Carprofen.

Pharmaceutical form

Tablet - Round, dark brown, marbled tablets with visible darker spots, one-side scored and bevel-edged.

The tablet can be divided into equal halves

Clinical particulars

Target species

Dogs

Indications for use

Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post operative pain.

Contraindications

Do not use in cats.

Do not use in pregnant or lactating bitches.

NOAH Compendium

Do not use in dogs less than 4 months of age.

Do not use in case of hypersensitivity to active substance or to any of the excipients.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia.

Special warnings for each target species

Refer to Contraindications and Special precautions for use

Special precautions for use

Special precautions for use in animals

Use in aged dogs may involve additional risk. If such a use cannot be avoided, dogs may require careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

In the event of accidental ingestion of the tablets, seek medical advice and show the doctor the package leaflet. Wash hands after handling the product.

Adverse reactions

Typical undesirable effects associated with NSAIDs such as vomiting, soft faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought.

As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.

Use during pregnancy, lactation or lay

Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose. The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Do not use in pregnant or lactating bitches.

NOAH Compendium

Interactions

Do not administer other NSAIDs and glucocorticoids concurrently or within 24 hours of administration of the product. Carprofen is highly bound to plasma proteins and may compete with other highly bound drugs, which can lead to toxic effects.

Concurrent administration of potential nephrotoxic drugs should be avoided

Amounts to be administered and administration route

For oral administration.

An initial dose of 2 to 4 mg carprofen per kg bodyweight per day is recommended to be given as a single or in two equally divided doses. Subject to clinical response, the dose may be reduced after 7 days to 2 mg carprofen/kg bodyweight/day given as a single dose.

To extend analgesic cover post-operatively, parenteral therapy with solution for injection may be followed with tablets at 4 mg/kg/day for up to 5 days.

Duration of treatment will be dependent upon the response seen, but the dog's condition should be re-appraised by the veterinary surgeon after 14 days therapy.

Overdose

Do not exceed the stated dose.

Although studies investigating the safety of carprofen at overdose have been performed, no signs of toxicity appeared when dogs were treated with carprofen at levels up to 6 mg/kg twice daily for 7 days (3 times the recommended dose rate of 4mg/kg) and 6mg/kg once daily for a further 7 days. (1.5 times the recommended dose rate of 4 mg/kg).

There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.

Withdrawal periods

Not Applicable

Pharmacological particulars

Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, nonsteroids, propionic acid derivatives.

ATCvet code: QM01AE91

Pharmacodynamic properties

Carprofen possesses anti-inflammatory, analgesic and antipyretic activity. Like most other NSAID's, carprofen is an inhibitor of the enzyme cyclo-oxygenase of the arachidonic acid cascade.

NOAH Compendium

However, the inhibition of prostaglandin synthesis by carprofen is slight in relation to its anti-inflammatory and analgesic potency. The precise mode of action of carprofen is not clear.

Carprofen is a chiral drug with the S(+) enantiomer being more active than the R(-) enantiomer. There is no chiral inversion between the enantiomers *in-vivo*.

Pharmacokinetic properties

Carprofen is well absorbed after oral administration ([>90%) and is highly protein bound. Peak plasma concentrations are achieved between 1 h and 3 h after administration.

Carprofen is characterized by a half-life of approximately 10 hours in dogs.

Carprofen is eliminated in dogs primarily by means of biotransformation in the liver, followed by rapid excretion of the resulting metabolites in faeces (70-80%) and urine (10-20%). Some enterohepatic circulation has been detected.

Pharmaceutical particulars

Excipients

Lactose monohydrate

Maize starch

Ferric oxide red (E172)

Ferric oxide black (E172)

Povidone K30

Sodium starch glycolate, type A

Colloidal anhydrous silica

Meat flavour 10022

Talc

Magnesium stearate

Shelf life

Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

Return any halved tablet to the opened blister and use within 24 hours.

Special precautions for storage

Do not store above 25°C.

Store in the original package in order to protect from light and moisture.

Immediate packaging

NOAH Compendium

10 tablets per blister strip.

20mg x 20 tablets

50mg x 100 tablets

100mg x 100 tablets

Not all pack sizes may be marketed.

Disposal

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Marketing Authorisation Holder (if different from distributor)

KRKA, d.d., Novo mesto

Šmarješka cesta 6

8501 Novo mesto

Slovenia

Marketing Authorisation Number

Carprox Vet 20mg Vm 01656/4010

Carprox Vet 50mg Vm 01656/4012

Carprox Vet 100mg Vm 01656/4013

Significant changes

Date of the first authorisation or date of renewal

19 November 2010

Date of revision of the text

March 2020

Any other information

Nil

Legal category

Legal category:POM-V

GTIN

GTIN description:Carprox Vet 20mg

GTIN:03838989626815

NOAH Compendium

GTIN description:Carprox Vet 50mg

GTIN:03838989626822

GTIN description:Carprox Vet 100mg

GTIN:03838989626839